PYMNTS.com January 26, 2025

The past few weeks have seen hopeful reports about an IPO resurgence.

But as Reuters reported Friday (Jan. 24), some Wall Street analysts are urging caution following a lukewarm reaction to Venture Global’s valuation target for its initial public offering (IPO).

That company had hoped for a $110 billion price tag but settled for a 45% downgrade when it finally sold shares last week.

“Even with the improved market sentiment we’ve seen, investors are going to continue scrutinizing deals carefully,” said IPOX CEO Josef Schuster. “They aren’t broadly willing to pay overvalued companies when there are readily available market comparisons.”

The Reuters report noted that the pushback against Venture Global’s initial target was something of a surprise, considering a rising...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Investments, Mergers & Acquisitions / JV, Trends
Zoom invests in AI startup Suki
What's next for healthcare private equity?
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs
Private equity deal would set stage for 3-way Walgreens split: Report
Rare Disease Biotech Zevra Therapeutics to Sell FDA Drug Review Fast Pass for $150M

Share This Article